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Summary 
Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease marked by hyperglycemia 
and mononuclear cell infiltration of insulin-producing/3 islet cells. Predisposition to IDDM in 
humans has been linked to the class II major histocompatibility complex (MHC), and islet cells 
often become aberrantly class II positive during the course of the disease. We have used two 
recently described transgenic lines to investigate the role of class II molecules and CD4 + T cells 
in the onset of autoimmune insulitis.  Mice that are class II deficient  secondary to a targeted 
disruption of the A/3  b gene were bred to mice carrying a transgene for the lymphocytic cho- 
riomenigitis virus (LCMV) glycoprotein (GP) targeted to the endocrine pancreas.  Our results 
indicate that class II-deficient animals with and without the GP transgene produce a normal 
cytotoxic T lymphocyte response to whole LCMV. After infection with LCMV, GP-transgenic 
class II-deficient animals develop hyperglycemia as rapidly as their class II-positive littermates. 
Histologic examination of tissue sections from GP-transgenic class II-deficient animals reveals 
lymphocytic infiltrates  of the pancreatic islets that are distinguishable from those of their class 
II-positive littermates only by the absence of infiltrating CD4 + T  cells. These results suggest 
that in this model of autoimmune diabetes, CD4 + T cells and MHC class II molecules are not 
required for the development of disease. 
I 
nsulin-dependent diabetes  mellitus (type I;  IDDM) 1 is 
. caused by the autoimmune destruction of insulin-producing 
/3 cells in pancreatic islets of Langerhans (1). The disease is 
associated with hypoinsulinemia, hyperglycemia, and mono- 
nuclear cell infiltration in the islets. The development of dia- 
betes appears to be multifactorial and has both genetic and 
environmental contributions. Predisposition to type I diabetes 
is genetically determined and recent studies have linked mul- 
tiple haplotypes of the MHC class II locus with either an 
increased risk of disease or a protective effect (2). As well, 
the aberrant expression of class II molecules on the/3 cells 
of diabetic individuals has focused attention on the role of 
the MHC in the development of diabetes (3). In susceptible 
individuals, the development of diabetes is associated with 
1 Abbreviations used in  this paper: GE  glycoprotein;  IDDM,  insulin- 
dependent diabetes mellitus; LCMV, lymphocytic  choriomeningitis virus; 
RIP, rat insulin promoter. 
a loss of self-tolerance and immunologic destruction of pan- 
creatic/3 cells (4). 
Recently, transgenic animals expressing foreign genes under 
the control of the tissue-specific insulin promoter have been 
used as experimental models to study the development of 
insulin-dependent diabetes. Ectopic pancreatic expression of 
either MHC class I or II is not sufficient to produce autoim- 
mune insulitis (5-8). Hyperglycemia does occur, presumably 
due to interference by the transgene with insulin gene ex- 
pression or secretion (5). Diseased  transgenic animals also 
lack histologic evidence of mononuclear cell infiltration of 
the pancreas. Ectopic IFN-3' expression in pancreatic islets 
does lead to mononuclear cell infiltration and diabetes mel- 
litus (8, 9); however, hyperglycemia develops very rapidly and 
mononuclear cell infiltrates can be found in other endocrine 
glands.  Thus, previous transgenic models do not accurately 
reproduce the pathophysiology of diabetes. 
A transgenic model of insulin-dependent diabetes mellitus 
that mirrors the mononuclear cell infiltration and loss of self- 
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When the lymphocytic choriomeningitis virus (LCMV) gly- 
coprotein was expressed in the islets of Langerhans of trans- 
genie mice under the control of the rat insulin promoter (RIP), 
challenge with I.CMV resulted in a mononudear cell infihrate 
isolated to islet cells  and the onset of type I diabetes,  i.e., 
hyperglycemia and hypoinsulinemia (10). In a similar model, 
the onset of hyperglycemia could be prevented by treating 
mice with mAb to either CD4 or CD8 before LCMV chal- 
lenge (11). 
To further examine the requirement for CD4 cells and MI-IC 
class II in the development of diabetes, mice bearing the LCMV 
glycoprotein transgene were bred to MHC class II-deficient 
animals.  Mice deficient for MHC class II expression by virtue 
of a targeted disruption  of the A~  b gene have a profound 
reduction in the numbers of peripheral single-positive CD4 
cells (12). This is associated with an elevated number of CD8- 
positive T cells in the thymus and in the periphery. Although 
they have normal, or elevated, levels of serum IgM, the animals 
are unable to make IgG antibodies to T-dependent protein 
antigens. We report here that class II-deficient animals have 
a normal CTL response to LCMV and develop diabetes after 
LCMV infection in the presence of a glycoprotein transgene. 
Materials  and Methods 
Mouse Strains,  Target  Cells,  and Viruses. The transgenic  mouse 
line  GP34-20 bearing  LCMV  glycoprotein  (GP) under the  control 
of  the  rat  insulin  promoter has  been  previously  described  (10).  The 
class  II-deficient  mice  have  also  been  described  (12).  Founder mice 
in each  case  were crossed  to C57BI/6 mice;  the  F3 generation  was 
used  in  these  experiments.  Double transgenic  mice  were  generated 
by mating homozygous class  If-deficient  (A~  -/-)  mice to trans- 
genic  mice bearing  an LCMV  GP transgene  under the control  of 
the rat insulin  promoter. FI generation  mice transgenic  for the 
glycoprotein  and  heterozygous  at  the  class  II  locus  were  then  back- 
crossed  to class  II-deficient  mice to obtain  the class  II-deficient 
transgenic  mice.  In  all  experiments,  mice  were  heterozygous  at  the 
GP transgene  locus.  Mice were housed in microisolator  cages  and 
appeared  healthy.  MC57 (H-2  b)  i:ibroblasts  were grown in RPMI 
1640 supplemented with 7% FCS, 104  U penicillin/ml,  10  mg/ml 
streptomycin,  and I mM  t-glutamine.  The LCMV  ARM  done 
53b has been described  previously  (13),  as have  recombinant vac- 
cinia  viruses  expressing  LCMV  GP or  the  GP minimal CTL epitope 
peptide  GPI (glycoprotein  amino acids  32-42) (14).  Vaccinia  virus 
was titered  on 143 T4 ceils  and LCMV  on Veto ceils  (13,  14). 
Analysis  of  Blood  Glucose. Blood samples  were obtained  from 
the  retro-orbital  eye  plexus  of  mice at weekly intervals  and blood 
glucose measurements  were determined using Accu-Check  II 
(Boehringer Mannheim Biochemicals,  Indianapolis,  IN). 
Cytotoxicity  Assays. LCMV-specilic CTL were induced by in- 
traperitoneal  injection  of I0  s  PFU of  virus.  Hemi-splenectomies 
were performed 7 d after  infection.  Killing  by cytotoxic  T ceUs 
was quantitated  using  a  4-5-h SICr  release  assay  as  described  (13). 
Target cells were infected with either LCMV ARM or recombinant 
vaccinia virus expressing I.CMV GP or polypeptides for the LCMV 
CTL epitope GFI. Cells infected with LCMV ARM were at a mul- 
tiplicity of infection (MOI) of 1, and were incubated I h at 37~ 
with occasional rocking  and harvested after 48 h. Cells infected 
with vaccinia viruses were at a MOI of 3 and incubated 45 rain 
at 37~  Cells were washed, placed in fresh media, and harvested 
at 12 h. 2  ￿  106 target ceils were labeled with 1 mCi SlCr and 
plated at 104 cells/100 #1. Splenocytes were resuspended at 107/ml 
after lysis of RBC with 0.84% NH4C1. E/T ratios of 50:1, 25:1, 
and 12:1 were used. Samples were processed in triplicate and stan- 
dard deviation among  triplicates was <5%. 
Antibody Assays.  Antibodies  to whole LCMV were detected 
using an ELISA (15). Antibodies to LCMV GP were detected by 
staining  for plasma membrane  expression of LCMV in LCMV- 
infected MC57 cells with sera from infected animals as previously 
described (10). MC57 cells were used 48-72 h after infection with 
I.CMV ARM 53b. Specific  antibody was developed  with fluotescein- 
conjugated mAb to mouse IgG. Control sera were normal mouse 
preimmune  sera, anti-LCMV mAb, and hyperimmune serum ob- 
tained from a nontransgenic mouse 3 wk after infection with LCMV. 
Histology and lmmunohistochemistry.  Tissues  for histologic analysis 
were taken from animals 14 d after viral infection, fixed in 10% 
zinc formalin, and stained with hematoxylin and eosin (H&E). Im- 
munohistochemistry  was performed on 4-6-#m sections of liquid 
nitrogen  frozen tissue cut with a microtome. Sections were fixed 
briefly in 1% paraformaldehyde. Tissue was blocked with avidin 
and biotin (Vector  Labs, Burlingame, CA) and incubated with mAbs 
to class II,  CD4 (L3T4; Pharmingen),  or CD8 (Ly-2 and Ly-3; 
Pharmingen). Slides were incubated with biotinylated goat anti-rat 
IgG (Southern Biotec), followed by streptavidin horseradish per- 
oxidase and developed with 3,Y-diaminobenzidine in the presence 
of 0.03%  H202 for 5-20 min.  Slides were then  counterstained 
with hematoxylin. 
Results and Discussion 
CTL Response to I_CMV in MHC Class II--deficient Mic~  In 
pr  "ckminary  experiments,  we examined primary CTL responses 
to LCMV in homozygous class II-deficient (-/-)  animals 
as compared to heterozygous class II-positive (+/-)  litter- 
mates. Table I  presents the results of SlCr release assays per- 
formed on spleen cells obtained from class II-negative and 
class II-positive littermates 7 d after intraperitoneal injection 
of 10  s PFU of virus. Targets were MC57 fibroblasts infected 
with LCMV ARM 53b or vaccinia virus recombinants that 
contain either intact LCMV GP (vvGP) or a peptide epitope 
of GP (vvGP1, GP amino acids 32-42) that elicits a strong 
cytotoxic response. At an E/T ratio of 50:1, LCMV ARM-in- 
fected targets are lysed equally ef~eiently by class II-positive 
(specific  SlCr  release,  36%)  and class  II-negative  (spedfic 
SlCr release, 33%) splenic effectors. Chss II--defident animals 
also produce cytotoxic responses to glycoprotein (wGP) and 
a minimal GP epitope (wGPl) similar to that of both het- 
erozygous littermates and wild-type C57B1/6 H-2  b controls. 
These results were observed in multiple  experiments. 
We next asked whether this LCMV-specific immune re- 
sponse was also normal  in class  II-deficient  mice carrying 
the R.IP-GP transgene.  As detailed in Table 1, the CTL re- 
sponse dieited to whole LCMV 7 d after infection is equiva- 
lent in class II-ddicient (specific SlCr release at E/T of 50:1, 
22%)  and class  II-positive GP-transgenic  animals  (specific 
SlCr release at E/T of 50:1, 24%). Both class II-positive and 
class II-negative GP-transgenic mice also display CTL cyto- 
toxicity against H-28 cells infected with wGP and wGPl 
recombinants. However, in repeated experiments, transgenic 
mice consistently produce a slightly diminished CTL response 
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Source of day 7 splenic CTLs 
Mouse 
Percent  specific SlCr released  from H-2  z targets infected with: 
E/T  LCMV 
ratio  ARM  vvGP  vvGPl  Uninfected 
Class  II -/- 
(n  =  7) 
Class  II +/- 
(n  =  2) 
RIP-GP class  II -/- 
(,,  =  5) 
RIP-GP class  II § 
(n  =  4) 
Nontransgenic  H-2  b 
(n =  6) 
50:1  33  •  12  15  •  6  30  •  10  2  •  2 
25:1  25  •  8  15  •  6  24  •  8  1  •  1 
12.5:1  20  •  5  5  •  3  8  •  4  1  _+  0 
50:1  36  +  4  26  •  6  41  •  10  1  •  0 
25:1  18  •  6  25  •  5  26  •  8  3  •  1 
50:1  22  •  8  20  •  6  16  •  6  2  •  2 
25:1  11  •  4  16  +  4  7  •  3  1  _+  1 
12.5:1  5  •  3  11  •  5  5  •  2  1  •  1 
50:1  24  +  10  24  •  10  21  •  8  0  •  0 
25:1  20  +  8  16  •  6  15  •  6  1  •  0 
12.5:1  10  •  6  8  •  2  7  •  2  2  •  1 
50:1  32  •  4  17  •  8  33  •  8  3  +  2 
25:1  20  •  2  10  •  4  15  •  4  2  +  1 
CTL assays were performed 7 d after administering l0  s PFU LCMV intraperitoneally. Splenic lymphocyte effectors were used at E/T ratios of 50:1, 
25:1,  and 12.5:1. Targets were MC57 cells (H-2  b) labeled with SlCr and either uninfected or infected with LCMV-ARM or vaccinia virus (vv) 
recombinants containing LCMV GP or GP1 CTL epitopes. The values represent mean values +  SD. The difference in lysis between uninfected 
and infected MC57 cells was statistically significant (p ~0.01). 
to a given target when compared to their nontransgenic lit- 
termates (M. G. yon Herrath, unpublished observation). For 
example,  at an E/T  ratio of 50:1,  the percent  specific SlCr 
released from LCMV ARM-infected targets is 33% in class 
II-deficient animals and only 22% in class II-deficient animals 
with the GP transgene. The mechanism for this partial un- 
responsiveness remains unclear. T  cells with transgenic TCRs 
specific for LCMV GP are not deleted in mice with RIP-GP 
transgenes (11). This decreased cytotoxicity presumably repre- 
sents peripheral  anergy in  the presence of endogenous  GP 
that can be overcome by the strong immune response elicited 
by viral infection. 
These results  demonstrate  that  CD8 +  cells can mediate 
a  normal anti-LCMV  cytotoxic response in the  absence of 
CD4 + cells and class II-positive APCs.  Mice lacking CD4 
by homologous recombination have a normal CTL response 
to LCMV (16). Our data indicate that class II-positive APCs, 
as well, are not required for normal CD8-mediated antiviral 
effector function.  It has been reported that class II-deficien~ 
mice housed in conventional animal facilities exhibit a marked 
591  Laufer  et al. 
defect in their recall CTL response to influenza virus while 
mice housed in cleaner facilities have normal CTL responses 
(17). Our results are in agreement with the finding that class 
II-deficient animals housed in microisolator cages in a virus- 
free facility have efficient CTL responses  to virus and raise 
the possibility that class II-deficient animals  are unable  to 
clear  the routine  environmental  pathogens  present  in  con- 
ventional facilities. Overinfection with these organisms may 
lead to generalized immunosuppression  and the inability to 
appropriately  respond  to  a  nonroutine  pathogen  such  as 
influenza. 
In published studies, aduh mice depleted in vivo of CD4 
T  cells by mAbs generate  a  CTL  response to LCMV  that 
is reduced  by a  factor of 10 when  assayed by SlCr release, 
suggesting a limited requirement  for CD4 T  cells to main- 
tain CD8 function in this system (18-20).  Anti-CD4  treat- 
ment does not alter the clearance of LCMV in vivo (21). The 
role of T  cell help in the induction  of antiviral cytotoxicity 
is, however, dependent  on the virus studied.  Thus,  in vivo 
depletion of CD4 cells by antibody treatment quantitatively diminishes the cytotoxic response to vaccinia (22) and sendai 
(23); whereas the effect of antibody treatment on the response 
to ectromelia (24)  or herpes virus (25)  is minimal. 
Role of MHC Class II and CD4 Cells in LCMV-induced In- 
sulitis.  Transgenic mice expressing LCMV GP in the pan- 
creas are not tolerant of the transgenic protein since they de- 
velop IDDM after infection with LCMV (10, 11). To evaluate 
the requirement for class II expression and CD4 + cells in 
the development of autoimmune diabetes,  four 6-8-wk-old 
class II-positive (+/-)  and five class II-deficient (-/-)  lit- 
termates carrying LCMV transgenes were challenged with 
105 PFU of LCMV intraperitoneaUy and blood glucose levels 
were monitored weekly as detailed in Fig. 1. Those animals 
that developed hyperglycemia (blood sugar, >250 mg/dl) were 
killed. Class II deficiency is itself not associated with hyper- 
glycemia or mononuclear infiltration of pancreatic tissue: four 
uninfected class II-deficient animals examined between the 
ages of 6 wk and 6 mo had normal blood glucose levels and 
normal pancreatic histology by routine H&E  staining (T. 
Laufer, data not shown). LCMV challenge of 10  s PFU into 
five control nontransgenic class II-deficient and three het- 
erozygous littermates did not produce hyperglycemia  and none 
of the infected animals in either group had a blood glucose 
level >225 mg/dl. In contrast, within 14 d of LCMV infec- 
tion, the RIP-GP class II-deficient animals had blood glu- 
coses that averaged 550  mg/dl and only one animal had a 
blood sugar <500 mg/dl. These values are not significantly 
different than the blood sugars of RIP-GP class II-positive 
littermates, whose blood glucose averaged 560 mg/dl on day 
14. Thus, class II deficiency does not alter the development 
of hyperglycemia induced in transgenic animals by LCMV 
infection. 
Pancreatic sections were taken from hyperglycemic mice 
killed 14 d postinfection. The tissue sections reveal a lym- 
phocytic infiltrate restricted to the islets and sparing the exo- 
crine pancreas, and are indistinguishable in class II-positive 
and class II-negative littermates (Fig. 2, b and c). To further 
characterize the pathologic process within the islets of Lang- 
erhans, additional pancreatic sections were stained with mAbs 
to CD4 and CD8 (Fig. 3). In class II-positive RIP-GP mice, 
the lymphocytic infiltrate was composed of both CD4 and 
CD8 cells (Fig.  3, a-c).  Conversely (Fig.  3, d-J), the lym- 
phocytic infiltrate present in the islets of RIP-GP class II-nega- 
tive animals was uniformly CD8 +. Thus, in R.IP-GP  mice 
that are class II deficient, CD8 + cells are sufficient to me- 
diate  the  development  of an  islet-restricted  lymphocytic 
infiltrate and hyperglycemia after LCMV infection. 
Antibody Response to LCMV in Class II-deficient  RIP-GP 
Mice.  It has been previously described that class II-defident 
animals fail to produce antigen-specific antibodies to soluble 
protein antigen (12). Fig. 4 a demonstrates that despite normal 
CTL reactivity to LCMV in the absence of CD4 cells and 
class II, the anti-LCMV antibody response remained depen- 
dent on the class II status of the animal. Three nontrans- 
genic class II-positive animals assayed before LCMV infec- 
tion had anti-LCMV titers of <1:10 plasma dilution. When 
serum obtained 14 d after challenge with 10  s PFU of LCMV 
intraperitoneally was assayed in an ELISA with whole soni- 
cated virus, all class II heterozygous mice had significant an- 
tibody responses with titers averaging 1:3,500  and ranging 
from 1:150 to 1:10,000.  In contrast, seven class II-deficient 
animals failed to produce LCMV-specific antibodies and had 
titers in the ELISA that averaged 1:30 and ranged from 1:1 
to 1:50. Antibody specific to LCMV GP was assayed by im- 
munofluorescent staining of LCMV-infected MC57 cells with 
sera at 1:10 dilutions from transgenic animals 14 d after viral 
infection. Serum from class II-positive animals had evidence 
of fluorescent staining of the MC57 cells (Fig.  4 c).  Class 
II-negative animals, in contrast, failed to produce detectable 
antibody (Fig.  4 d). 
Our results indicate that in the absence of a functional popu- 
lation of class II-restricted CD4 + helper cells,  class II-re- 
stricted CD8 + cells can provide help for the generation of 
cytotoxicity. This situation has some analogy to the develop- 
ment  of LCMV-specific  class  II-restricted  CD4 +  CTLs 
identified by Muller et al. (26) in 32-microglobulin-deficient 
mice that lack class I  and,  therefore, CD8 + cells.  In that 
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Figure  1.  Hyperglycemia  after LCMV  Infection. 
The occurrence of IDDM in ILIP-LCMV transgenic 
mice after LCMV infection. Littermates at 6-8 wk 
of age received 105 PFU of LCMV intraperitoneaUy. 
Mice were subsequently bled and blood glucose levels 
were measured as described in Materials and Methods. 
592  Autoimmune Diabetes in Class II-deficient Mice Figure  2.  Islets of Langerhans  from mice 14 d after viral infection.  Pancreatic sections from individual class II--deficient nontransgenic (a), RIP-GP 
class II-positive (b), and RIP-GP class II-negative animals stained with H&E. Note the mononudear cell infiltrates restricted to the islets in b and c. 
Figure  3.  Immunohistochemistry of islets of Langerhans  after viral infection. ILIP-GP class II-positive (a--c) or negative (d-J) animals received 10  5 
pfu of LCMV intraperitoneally. 14 d after infection, pancreases were removed and sectioned.  Immunohistochemistry was performed using no primary 
antibody (a and d), anti-CD4 (b and e), or anti-CD8 (c and J). 
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Sample  Antibody, titer 
Normal mouse  < 1:10• 
Prtirranune serum 
(n=2) 
Class II +/-  1:3500+_1700 
(n-5) 
Class II 4-  1:30+_.i  i 
(n--7) 
Normal mouse  1:7600+_1600 
Hyperimmune serum 
(n=l) 
Figure  4.  Sera  from  class II-deficient 
animals challenged with LCMV lack spe- 
cific antibodies (a). Sera from infected mice 
were assayed in an ELISA to whole soni- 
cared LCMV. The reactions were developed 
with a secondary anti-mouse IgG-peroxi- 
dase conjugate. Titers represent the dilu- 
tion at which  the OD492  =  0.3  _+  SD. 
(b-d) Antibodies to LCMV GP from class 
II-heterozygous  (c) or -deficient (d) animals 
were detected by immunofluorescence  of 
LCMV-infected  MC57  cells  with  sera 
diluted 1:10. The positive control panel (b) 
is serum obtained from a wild-type H-2b 
mouse 3 wk after LCMV challenge. 
the LCMV-specific CTL response in normal B6 mice, sug- 
gesting a very low frequency of CD4 + CTL precursors nor- 
mally. In dass II-defident animals, a population of dass I-re- 
stricted, CD8 + cells that can produce cytokines may develop 
to substitute for the CD4 + help typically generated. How- 
ever, such a population may not normally exist. This may 
account for the reduction of anti-LCMV cytotoxicity  in normal 
mice by treatment with anti-CD4  antibody, which is not 
seen in mice that are CD4- or dass II-deficient from birth. 
It may also explain Ohashi et al.'s (11) finding that wild-type 
H-2  s  RIP-GP  transgenics fail  to  develop hyperglycemia if 
anti-CD4 antibody is given before LCMV infection. Alter- 
natively, the cytotoxic response to LCMV may be an inde- 
pendent response that does not require cytokin~mediated  help. 
We favor the first possibility, as evidence exists in other mu- 
fine systems for production of cytokines by CD8 + cells in 
response to "allo" differences (27,  28),  mitogenic stimula- 
tion (29), and stimulation with immobilized anti-CD3 (30), 
and preliminary experiments suggest that IL-2 is elaborated 
by primary LCMV CTL cultures from class II-defident mice 
(M.  G.  yon Herrath,  unpublished observation). 
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